039200.KQ
Oscotec Inc.
KOE · Healthcare · Drug Manufacturers - General · KR
KRW 35,900.00
−1.91%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 144.2B | 99.8B | 34.0B | 5.0B | 5.1B |
| Cost of Revenue | 2.7B | 1.9B | 2.2B | 2.0B | 3.5B |
| Gross Profit | 141.5B | 97.9B | 31.8B | 2.7B | 1.6B |
| Operating Expenses | |||||
| R&D Expense | 30.6B | 27.6B | 21.4B | 24.9B | 23.3B |
| SG&A Expense | 11.6B | 7.5B | 4.4B | 8.5B | 6.2B |
| General & Admin Expense | 3.9B | 2.1B | 1.6B | 2.2B | 1.6B |
| Selling & Marketing Expense | 7.7B | 5.3B | 2.8B | 1.7B | 1.1B |
| Other Expenses | 19.5B | 10.7B | 8.6B | 6.8B | 5.5B |
| Total Operating Expenses | 51.7B | 45.8B | 34.5B | 33.4B | 29.6B |
| Cost and Expenses | 54.5B | 47.8B | 36.7B | 37.6B | 33.6B |
| Operating Income (EBIT) | 89.7B | 52.1B | (2.7B) | (32.7B) | (28.5B) |
| Non-Operating | |||||
| Interest Income | 4.6B | 3.9B | 4.0B | 4.8B | 1.2B |
| Interest Expense | 2.6B | 2.3B | 1.1B | 406.6M | 316.4M |
| Net Interest Income | 2.0B | 1.7B | 2.9B | 4.4B | 904.0M |
| Other Non-Op Income/Expense | 9.1B | 706.0M | 1.6B | 371.8M | 532.8M |
| Non-Operating Income (excl Interest) | (3.1B) | (3.0B) | (2.7B) | 1.2B | (849.2M) |
| EBT (Pre-Tax Income) | 98.8B | 52.8B | (1.1B) | (32.3B) | (28.0B) |
| Income Tax Expense | (1.6B) | (1.6B) | 471.9M | (3.8B) | (209.3M) |
| Bottom Line | |||||
| Net Income | 94.3B | 52.6B | 876.5M | (24.3B) | (24.4B) |
| Earnings from Cont. Ops | 100.4B | 54.4B | (1.6B) | (28.5B) | (27.8B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 94.3B | 52.6B | 876.5M | (24.3B) | (24.4B) |
| Per Share | |||||
| Basic EPS | ₩2,464 | ₩1,368 | ₩23 | (₩635) | (₩763) |
| Diluted EPS | ₩2,464 | ₩1,368 | ₩23 | (₩635) | (₩763) |
| Revenue Per Share | ₩3,769 | ₩2,610 | ₩889 | ₩129 | ₩158 |
| Shares | |||||
| Basic Shares Outstanding | 38.3M | 38.3M | 38.2M | 38.2M | 32.0M |
| Diluted Shares Outstanding | 38.3M | 38.3M | 38.2M | 38.2M | 32.0M |
| Profitability Metrics | |||||
| EBITDA | 92.5B | 53.7B | 1.9B | (30.0B) | (26.0B) |
| D&A | 1.4B | 1.5B | 1.9B | 1.9B | 1.6B |
| EBIT | 91.4B | 55.1B | (32.5M) | (31.9B) | (27.7B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026